INSM Q2 2025 Earnings — Insmed Incorporated Revenue & Financial Results | Market Cap Arena

INSMInsmed Incorporated

$31B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$107M+18.9% YoY

Gross Profit

$79M73.9% margin

Operating Income

-$313M-291.3% margin

Net Income

-$322M-299.5% margin

EPS (Diluted)

$-1.70

QoQ Revenue Growth

+15.7%

Cash Flow

Operating Cash Flow

-$206M

Free Cash Flow

-$209M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$2.5B

Total Liabilities

$1.2B

Stockholders' Equity

$1.2B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$107M	$90M	+18.9%
Gross Profit	$79M	$69M	+14.4%
Operating Income	-$313M	-$289M	-8.3%
Net Income	-$322M	-$301M	-7.0%

Revenue Segments

Reportable Segment

$107M100%

Geographic Segments

UNITED STATES

$69M64%

JAPAN

$31M29%

Europe And The Rest Of The World

$8M8%